<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895345</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2450-II-11</org_study_id>
    <nct_id>NCT04895345</nct_id>
  </id_info>
  <brief_title>A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma</brief_title>
  <official_title>An Open, Single-arm, Single-center, Phase II Clinical Trial of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the efficacy and safety of TQB2450 injection combination with&#xD;
      Intensity-modulated Radiotherapy in patients with inoperable locally recurrent nasopharyngeal&#xD;
      carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate（DCR）</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>The time when the participants first achieved complete or partial remission to disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>PFS defined as the time from first dose until the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month progression-free survival rate</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>12-month PFS defined as the time from first administration until the first documented progressive disease (PD) or death from any cause within 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month survival rate</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>12-month survival rate defined as the time from first administration to death from any cause within 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-month survival rate</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>24-month survival rate defined as the time from first administration to death from any cause within 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local regional recurrence-free survival (LRRFs)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>The time interval between the patient's first medication and the appearance of local imaging progress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival (DMFS)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>The time interval between the patient's first medication and the appearance of distant metastasis imaging progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>TQB2450+Intensity modulated radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day；The total dose of radiotherapy should meet PTVnx: 60Gy/27Fr/2.22Gy, PTVnd: 60-64Gy/27Fr/2.22-2.37Gy, PTV1: 54Gy/27Fr/2.00Gy, once a day, 5 times/week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2450</intervention_name>
    <description>TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.</description>
    <arm_group_label>TQB2450+Intensity modulated radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity modulated radiotherapy</intervention_name>
    <description>Intensity-modulated conformal radiotherapy (IMRT) is a kind of three dimensional conformal radiotherapy, which requires the dose intensity in the radiation field to be adjusted according to certain requirements.</description>
    <arm_group_label>TQB2450+Intensity modulated radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Understood and Signed an informed consent form; 2. Eastern Cooperative Oncology&#xD;
             Group (ECOG) performance status of 0 to 1; Life expectancy ≥ 3 months; 3. Local&#xD;
             recurrence of non-keratinizing nasopharyngeal carcinoma diagnosed by histopathology&#xD;
             and/or cytology; Clinical stage: rT2-4N0-3M0 , RII-IVa phase (AJCC eighth edition); 4.&#xD;
             The recurrence time is more than 12 months from the end of the first course of&#xD;
             radiotherapy, without other systemic or local anti-tumor treatment; 5. At least one&#xD;
             measurable lesion (based on RECIST 1.1); 6. Adequate laboratory indicators; 7. No&#xD;
             pregnant or breastfeeding women, and a negative pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Operable patients with local recurrence, including rT2 (the tumor is confined to&#xD;
             the surface of the parapharyngeal space, and the distance from the internal carotid&#xD;
             artery &gt; 0.5 cm) and rT3 (the tumor is confined to the bottom wall of the sphenoid&#xD;
             sinus, and the distance from the internal carotid artery and cavernous sinus &gt; 0.5 cm)&#xD;
             ; 2.Combined diseases and medical history:&#xD;
&#xD;
               1. Accompanied by nasopharyngeal necrosis, radiation brain injury, severe neck&#xD;
                  fibrosis, or other ≥grade 3 radiation complications, the investigator has&#xD;
                  assessed that the risk is extremely high and not suitable for radiotherapy;&#xD;
&#xD;
               2. Has other malignant tumors within 3 years;&#xD;
&#xD;
               3. Unalleviated toxicity ≥ grade 1 due to any previous anticancer therapy;&#xD;
&#xD;
               4. Has received major surgical treatment, open biopsy, or obvious traumatic injury&#xD;
                  within 28 days before the first administration;&#xD;
&#xD;
               5. Long-term unhealed wounds or fractures;&#xD;
&#xD;
               6. Arterial/venous thrombosis events occurred within 6 months, such as&#xD;
                  cerebrovascular accidents (including temporary ischemic attacks, cerebral;&#xD;
                  hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism;&#xD;
&#xD;
               7. Has drug abuse history that unable to abstain from or mental disorders;&#xD;
&#xD;
               8. Has any severe and/or uncontrollable disease. 3.Tumor-related symptoms and&#xD;
                  treatment:&#xD;
&#xD;
               1. Diagnosed local recurrence and received surgery, chemotherapy, radiotherapy or&#xD;
                  other anti-cancer therapies before first administration;&#xD;
&#xD;
               2. Has received NMPA approved Chinese patent medicines with anti-tumor indications;&#xD;
&#xD;
               3. Has received relevant immunotherapy drugs for PD-1, PD-L1, CTLA-4, etc.;&#xD;
&#xD;
               4. Uncontrollable pleural effusion, pericardial effusion or ascites that still needs&#xD;
                  to be drained repeatedly (as judged by the investigator); 4.Research and&#xD;
                  treatment related:&#xD;
&#xD;
               1. Has vaccinated with vaccines or attenuated vaccines within 4 weeks prior to first&#xD;
                  administration;&#xD;
&#xD;
               2. Have severe hypersensitivity after using monoclonal antibodies;&#xD;
&#xD;
               3. Active autoimmune diseases that require systemic treatment (such as the use of&#xD;
                  disease-relieving drugs, corticosteroids, or immunosuppressive agents) occurred&#xD;
                  within 2 years before the start of the study treatment;&#xD;
&#xD;
               4. Has immunodeficiency or received systemic glucocorticoid therapy or any other&#xD;
                  form of immunosuppressive therapy, and continue to use within 2 weeks of the&#xD;
                  first administration; 5.Has participated in other anti-tumor drug clinical trials&#xD;
                  within 4 weeks before the study; 6.According to the judgement of the&#xD;
                  investigators, there are other factors that may lead to the termination of the&#xD;
                  study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingyuan Chen, Doctor</last_name>
      <phone>020-87343633</phone>
      <email>chenmy@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Mingyuan Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

